Mirum Historical Income Statement
| MIRM Stock | USD 46.65 1.50 3.32% |
Historical analysis of Mirum Pharmaceuticals income statement accounts such as Selling General Administrative of 146.6 M can show how well Mirum Pharmaceuticals performed in making a profits. Evaluating Mirum Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Mirum Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Mirum Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Mirum Pharmaceuticals is a good buy for the upcoming year.
Mirum |
About Mirum Income Statement Analysis
Mirum Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Mirum Pharmaceuticals shareholders. The income statement also shows Mirum investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Mirum Pharmaceuticals Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Mirum Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Mirum Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Mirum Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Mirum Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Mirum Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.At this time, Mirum Pharmaceuticals' Income Tax Expense is very stable compared to the past year. As of the 28th of November 2024, Tax Provision is likely to grow to about 951.3 K, while Other Operating Expenses is likely to drop about 156.8 M.
Mirum Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Mirum Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Mirum Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Income | 2.2M | 1.6M | 366K | 3.9M | 12.1M | 12.7M | |
| Interest Expense | 2.5M | 335K | 17.6M | 16.0M | 15.1M | 9.4M | |
| Selling General Administrative | 11.8M | 22.7M | 59.2M | 17.0M | 139.6M | 146.6M | |
| Gross Profit | (324K) | (623K) | 17.2M | 64.7M | 139.3M | 146.3M | |
| Other Operating Expenses | 54.7M | 104.3M | 192.6M | 208.3M | 295.5M | 156.8M | |
| Operating Income | (54.7M) | (104.3M) | (173.4M) | (131.2M) | (109.2M) | (114.6M) | |
| Net Income From Continuing Ops | (52.6M) | (103.3M) | (84.0M) | (135.7M) | (164.2M) | (156.0M) | |
| Ebit | (54.7M) | (102.9M) | (66.4M) | (126.1M) | (147.3M) | (140.0M) | |
| Research Development | 43.0M | 81.6M | 131.4M | 106.8M | 102.6M | 86.0M | |
| Cost Of Revenue | 324K | 623K | 1.9M | 12.4M | 47.0M | 49.4M | |
| Total Operating Expenses | 54.7M | 104.3M | 190.6M | 195.9M | 248.5M | 146.4M | |
| Income Before Tax | (52.5M) | (103.3M) | (84.0M) | (142.1M) | (162.4M) | (154.3M) | |
| Total Other Income Expense Net | 2.2M | 1.0M | 89.5M | (10.9M) | (53.3M) | (50.6M) | |
| Net Income Applicable To Common Shares | (52.6M) | (103.3M) | (84.0M) | (135.7M) | (122.1M) | (128.2M) | |
| Net Income | (52.6M) | (103.3M) | (84.0M) | (135.7M) | (163.4M) | (155.2M) | |
| Income Tax Expense | 21K | 6K | 37K | (6.4M) | 991K | 1.0M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 6.513 | Quarterly Revenue Growth 0.894 | Return On Assets (0.09) | Return On Equity (0.40) |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.